JP2008516909A5 - - Google Patents

Download PDF

Info

Publication number
JP2008516909A5
JP2008516909A5 JP2007536082A JP2007536082A JP2008516909A5 JP 2008516909 A5 JP2008516909 A5 JP 2008516909A5 JP 2007536082 A JP2007536082 A JP 2007536082A JP 2007536082 A JP2007536082 A JP 2007536082A JP 2008516909 A5 JP2008516909 A5 JP 2008516909A5
Authority
JP
Japan
Prior art keywords
use according
disease
symptoms
symptom
receptor agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007536082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008516909A (ja
Filing date
Publication date
Priority claimed from DE102004050952A external-priority patent/DE102004050952A1/de
Application filed filed Critical
Priority claimed from PCT/EP2005/010975 external-priority patent/WO2006042679A1/de
Publication of JP2008516909A publication Critical patent/JP2008516909A/ja
Publication of JP2008516909A5 publication Critical patent/JP2008516909A5/ja
Pending legal-status Critical Current

Links

JP2007536082A 2004-10-18 2005-10-12 前立腺及び下部泌尿生殖路の病気を治療するためのβ−３アゴニストの使用 Pending JP2008516909A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004050952A DE102004050952A1 (de) 2004-10-18 2004-10-18 Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
US62459004P 2004-11-03 2004-11-03
PCT/EP2005/010975 WO2006042679A1 (de) 2004-10-18 2005-10-12 Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts

Publications (2)

Publication Number Publication Date
JP2008516909A JP2008516909A (ja) 2008-05-22
JP2008516909A5 true JP2008516909A5 (enExample) 2008-11-27

Family

ID=36202691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007536082A Pending JP2008516909A (ja) 2004-10-18 2005-10-12 前立腺及び下部泌尿生殖路の病気を治療するためのβ−３アゴニストの使用

Country Status (6)

Country Link
US (1) US20060084700A1 (enExample)
EP (1) EP1804778A1 (enExample)
JP (1) JP2008516909A (enExample)
CA (1) CA2580170A1 (enExample)
TW (1) TW200630083A (enExample)
WO (1) WO2006042679A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
CA2630818A1 (en) * 2005-11-28 2007-05-31 Kissei Pharmaceutical Co., Ltd. Pharmaceutical composition for prevention or treatment of neurogenic pain
US20090312242A1 (en) * 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
US20100113469A1 (en) * 2007-03-29 2010-05-06 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
CA2774992A1 (en) * 2009-10-07 2011-04-14 Merck Sharp & Dohme Corp. Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
SG187689A1 (en) * 2010-08-03 2013-03-28 Altherx Inc Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
EP3226849A4 (en) 2014-12-03 2018-05-09 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
US7208520B2 (en) * 2001-09-13 2007-04-24 Kissei Pharmaceutical Co., Ltd. Crystals of hydroxynorephedrine derivative
DE10251170A1 (de) * 2002-10-31 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
EP1539181B1 (en) * 2003-04-04 2007-06-27 Dynogen Pharmaceuticals Inc. Method of treating lower urinary tract disorders
US20050222247A1 (en) * 2003-12-13 2005-10-06 Bayer Healthcare Ag Chroman derivatives

Similar Documents

Publication Publication Date Title
JP2006523216A5 (enExample)
JP2007514005A5 (enExample)
JP2008539268A5 (enExample)
JP2009506117A5 (enExample)
JP2011522816A5 (enExample)
JP2005506370A5 (enExample)
JP2006143751A5 (enExample)
JP2008516909A5 (enExample)
JP2005527599A5 (enExample)
EP2283843A3 (en) Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
JP2007504174A5 (enExample)
JP2012512158A5 (enExample)
JP2010518122A5 (enExample)
JP2009535370A5 (enExample)
WO2008058288A3 (en) Sustained release methotrexate formulations and methods of use thereof
JP2012502037A5 (enExample)
JP2011516417A5 (enExample)
JP2008539267A5 (enExample)
JP2008528761A5 (enExample)
JP2008513510A5 (enExample)
JP2010500284A5 (enExample)
JP2008536853A5 (enExample)
JP2009504774A5 (enExample)
JP2009518415A5 (enExample)
JP2003520208A5 (enExample)